Literature DB >> 27630236

A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I.

Adam Zuiani1, Kevin Chen2, Megan C Schwarz3, James P White4, Vincent C Luca5, Daved H Fremont1,2,6, David Wang1,2, Matthew J Evans3, Michael S Diamond7,2,4,8.   

Abstract

While natural hepatitis C virus (HCV) infection results in highly diverse quasispecies of related viruses over time, mutations accumulate more slowly in tissue culture, in part because of the inefficiency of replication in cells. To create a highly diverse population of HCV particles in cell culture and identify novel growth-enhancing mutations, we engineered a library of infectious HCV with all codons represented at most positions in the ectodomain of the E2 gene. We identified many putative growth-adaptive mutations and selected nine highly represented E2 mutants for further study: Q412R, T416R, S449P, T563V, A579R, L619T, V626S, K632T, and L644I. We evaluated these mutants for changes in particle-to-infectious-unit ratio, sensitivity to neutralizing antibody or CD81 large extracellular loop (CD81-LEL) inhibition, entry factor usage, and buoyant density profiles. Q412R, T416R, S449P, T563V, and L619T were neutralized more efficiently by anti-E2 antibodies and T416R, T563V, and L619T by CD81-LEL. Remarkably, all nine variants showed reduced dependence on scavenger receptor class B type I (SR-BI) for infection. This shift from SR-BI usage did not correlate with a change in the buoyant density profiles of the variants, suggesting an altered E2-SR-BI interaction rather than changes in the virus-associated lipoprotein-E2 interaction. Our results demonstrate that residues influencing SR-BI usage are distributed across E2 and support the development of large-scale mutagenesis studies to identify viral variants with unique functional properties. IMPORTANCE: Characterizing variant viruses can reveal new information about the life cycle of HCV and the roles played by different viral genes. However, it is difficult to recapitulate high levels of diversity in the laboratory because of limitations in the HCV culture system. To overcome this limitation, we engineered a library of mutations into the E2 gene in the context of an infectious clone of the virus. We used this library of viruses to identify nine mutations that enhance the growth rate of HCV. These growth-enhancing mutations reduced the dependence on a key entry receptor, SR-BI. By generating a highly diverse library of infectious HCV, we mapped regions of the E2 protein that influence a key virus-host interaction and provide proof of principle for the generation of large-scale mutant libraries for the study of pathogens with great sequence variability.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27630236      PMCID: PMC5110168          DOI: 10.1128/JVI.01011-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry.

Authors:  Heidi E Drummer; Irene Boo; Anne L Maerz; Pantelis Poumbourios
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

2.  Development of hepatitis C virus genotype 3a cell culture system.

Authors:  Sulyi Kim; Tomoko Date; Hiroshi Yokokawa; Tamaki Kono; Hideki Aizaki; Patrick Maurel; Claire Gondeau; Takaji Wakita
Journal:  Hepatology       Date:  2014-07-14       Impact factor: 17.425

3.  Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient.

Authors:  T Kato; A Furusaka; M Miyamoto; T Date; K Yasui; J Hiramoto; K Nagayama; T Tanaka; T Wakita
Journal:  J Med Virol       Date:  2001-07       Impact factor: 2.327

4.  Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.

Authors:  Michelle C Sabo; Vincent C Luca; Jannick Prentoe; Sharon E Hopcraft; Keril J Blight; Minkyung Yi; Stanley M Lemon; Jonathan K Ball; Jens Bukh; Matthew J Evans; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

5.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.

Authors:  P Farci; A Shimoda; A Coiana; G Diaz; G Peddis; J C Melpolder; A Strazzera; D Y Chien; S J Munoz; A Balestrieri; R H Purcell; H J Alter
Journal:  Science       Date:  2000-04-14       Impact factor: 47.728

6.  A laboratory-adapted HCV JFH-1 strain is sensitive to neutralization and can gradually escape under the selection pressure of neutralizing human plasma.

Authors:  Hongshuo Song; Furong Ren; Jin Li; Shuang Shi; Ling Yan; Feng Gao; Kui Li; Hui Zhuang
Journal:  Virus Res       Date:  2012-07-27       Impact factor: 3.303

7.  Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate.

Authors:  Heidi Barth; Christiane Schafer; Mohammed I Adah; Fuming Zhang; Robert J Linhardt; Hidenao Toyoda; Akiko Kinoshita-Toyoda; Toshihiko Toida; Toin H Van Kuppevelt; Erik Depla; Fritz Von Weizsacker; Hubert E Blum; Thomas F Baumert
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

8.  Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption.

Authors:  Raphaële Germi; Jean-Marc Crance; Daniel Garin; Josette Guimet; Hugues Lortat-Jacob; Rob W H Ruigrok; Jean-Pierre Zarski; Emmanuel Drouet
Journal:  J Med Virol       Date:  2002-10       Impact factor: 2.327

9.  Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains.

Authors:  Yi-Ping Li; Santseharay Ramirez; Judith M Gottwein; Troels K H Scheel; Lotte Mikkelsen; Robert H Purcell; Jens Bukh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-30       Impact factor: 11.205

10.  Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.

Authors:  Zhen-yong Keck; Jinming Xia; Yong Wang; Wenyan Wang; Thomas Krey; Jannick Prentoe; Thomas Carlsen; Angela Ying-Jian Li; Arvind H Patel; Stanley M Lemon; Jens Bukh; Felix A Rey; Steven K H Foung
Journal:  PLoS Pathog       Date:  2012-04-12       Impact factor: 6.823

View more
  9 in total

1.  Neutralization and receptor use of infectious culture-derived rat hepacivirus as a model for HCV.

Authors:  Raphael Wolfisberg; Caroline E Thorselius; Eduardo Salinas; Elizabeth Elrod; Sheetal Trivedi; Louise Nielsen; Ulrik Fahnøe; Amit Kapoor; Arash Grakoui; Charles M Rice; Jens Bukh; Kenn Holmbeck; Troels K H Scheel
Journal:  Hepatology       Date:  2022-05-12       Impact factor: 17.298

2.  Building a mechanistic mathematical model of hepatitis C virus entry.

Authors:  Mphatso Kalemera; Dilyana Mincheva; Joe Grove; Christopher J R Illingworth
Journal:  PLoS Comput Biol       Date:  2019-03-18       Impact factor: 4.475

3.  A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.

Authors:  Janelle Johnson; Holly Freedman; Michael Logan; Jason Alexander Ji-Xhin Wong; Darren Hockman; Chao Chen; Jianqi He; Michael R Beard; Nicholas S Eyre; Thomas F Baumert; D Lorne Tyrrell; John L M Law; Michael Houghton
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

4.  In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus.

Authors:  Christina Holmboe Olesen; Elias H Augestad; Fulvia Troise; Jens Bukh; Jannick Prentoe
Journal:  PLoS Pathog       Date:  2021-07-19       Impact factor: 6.823

5.  An entropic safety catch controls hepatitis C virus entry and antibody resistance.

Authors:  Lenka Stejskal; Mphatso D Kalemera; Charlotte B Lewis; Machaela Palor; Lucas Walker; Tina Daviter; William D Lees; David S Moss; Myrto Kremyda-Vlachou; Zisis Kozlakidis; Giulia Gallo; Dalan Bailey; William Rosenberg; Christopher J R Illingworth; Adrian J Shepherd; Joe Grove
Journal:  Elife       Date:  2022-07-07       Impact factor: 8.713

Review 6.  Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus.

Authors:  Thomas R Fuerst; Brian G Pierce; Zhen-Yong Keck; Steven K H Foung
Journal:  Front Microbiol       Date:  2018-01-15       Impact factor: 5.640

7.  Evolutionary Analysis Provides Insight Into the Origin and Adaptation of HCV.

Authors:  Diego Forni; Rachele Cagliani; Chiara Pontremoli; Uberto Pozzoli; Jacopo Vertemara; Luca De Gioia; Mario Clerici; Manuela Sironi
Journal:  Front Microbiol       Date:  2018-05-01       Impact factor: 5.640

Review 8.  Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine.

Authors:  Mei-Le Keck; Florian Wrensch; Brian G Pierce; Thomas F Baumert; Steven K H Foung
Journal:  Front Immunol       Date:  2018-05-31       Impact factor: 8.786

Review 9.  Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies.

Authors:  Rodrigo Velázquez-Moctezuma; Elias H Augestad; Matteo Castelli; Christina Holmboe Olesen; Nicola Clementi; Massimo Clementi; Nicasio Mancini; Jannick Prentoe
Journal:  Vaccines (Basel)       Date:  2021-03-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.